ALSA Ventures, a London based European biotech investment firm, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered a collaboration agreement to help develop and manufacture biologics and small molecule drug candidates for ALSA’s portfolio of pre-clinical and early clinical biotechs.
The biopharmaceutical industry is experiencing a global shift towards new molecular formats and more complex molecules, including bi- and multispecific antibodies, fusion proteins, and various types of bioconjugates. In addition, small molecules continue to play a vital role in innovative treatments. As these therapies gain complexity in their applications and properties, unique challenges related to their bioavailability and handling arise. Developing and manufacturing these increasingly complex modalities requires sophisticated facility design and expertise, which is often challenging to establish in-house.
